| HRA006166
(Open Access)
|
We prospectively enrolled and collected endoscopic biopsy samples from 12 patients with advanced ESCC treated with tislelizumab. Plasma was collected before and after every 2-3 treatment cycle of tislelizumab and when disease progression. Targeted sequencing of 425 genes on plasma cell-free DNA, DNA from leukocytes, and fixed esophageal tumor biopsies were performed. The patients underwent imaging analyses every 6-8 weeks until disease progression. The association between status and changes in circulating tumor DNA (ctDNA) following tislelizumab immunotherapy and response, tumor progression, and survival was determined. |
